Health Care · Pharmaceutical Preparations

LGND LIGAND PHARMACEUTICALS INC SEC Filings & Insider Trading Activity 2026

company
CIK 886163139 filings
Russell 2000

LGND at a glance

LIGAND PHARMACEUTICALS INC (LGND, SEC CIK 886163) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), LIGAND PHARMACEUTICALS INC (LGND) reported revenue of $268.1 million (up 60.4% from FY2024) and net income of $124.5 million. Diluted EPS was $6.13.
  • As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding LIGAND PHARMACEUTICALS INC (LGND) shares worth $3.4 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by KOZARICH JOHN W on November 12, 2026 of 500 shares at $325.00 per share.
  • In the last 90 days, LGND insiders reported 0 open-market purchases ($0) and 40 open-market sales ($7.4M) on Form 4, a net sale of $7.4M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$268.1M
+60.4% vs prior year
Insiders · 90 days
0 buys · 40 sells
Net −$7.4M
13F holders
32 funds
$3.4B · +0 vs prior quarter
Latest 8-K
Oct 29, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: biopharmaceutical royalty company focused on capital deployment and licensing for diversified royalty streams from mid- to late-stage products
  • New emphasis on NITRICIL platform acquired via Novan in 2023, supporting multiple royalty-bearing products including FDA-approved Zelsuvmi
  • Strategic refinement since 2022 to a high-margin, low-infrastructure model after spinoffs of OmniAb, Pelican Expression, and Pelthos Therapeutics
  • Invested $50 million in Castle Creek's D-Fi Phase 3 gene therapy and $25 million in Orchestra BioMed late-stage cardiology programs in 2025
  • Expanded royalty portfolio to 12 major commercial royalties and over 90 additional programs, showing growing diversity and disciplined capital allocation

Risk Factors

  • Regulatory risk: Section 162(m) limitation increased tax expense by $3.9 million (156%) in 2024 affecting effective tax rate
  • Macroeconomic threat: $460 million 2030 Notes issued in August 2025 increases interest expense by $1.7 million (55%) vs prior year
  • Operational risk: Deconsolidation of Novan acquisition payments from July 1, 2025 impacts interest accrued and financial reporting
  • Market disruption risk: Unrealized fair value loss $5.1 million on Viking common stock in 2025 vs $9.0 million gain in 2024
  • Financial risk: Concentration in equity method investments, e.g., $90.7 million gain from Pelthos stock fair value changes in 2025

Management Discussion & Analysis

  • No forward-looking statements or guidance mentioned

AI summary of the LGND 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue and income $78.7M, down $36.7M or 32% YoY from $115.5M
  • Net loss $28.5M vs net income $117.3M; operating costs 120% of revenue vs 52% YoY
  • Best performer royalties $70.3M, up 51%; Filspari royalty revenue $16.8M vs $9.1M
  • Cash, equivalents and short-term investments $447.4M vs $733.5M at December 31, 2025; operating cash flow $45.1M YTD
  • XOMA acquisition and investments drove liquidity decline; management expects resources sufficient for at least twelve months

Risk Factors

  • New acquisition risk triggered by July 14, 2026 XOMA Acquisition: integration may disrupt systems, personnel retention and royalty portfolio administration
  • Royalty revenue risk: counterparties may buy out obligations below future royalties’ net present value
  • Debt liquidity risk: 2030 Notes and 2031 Notes may require cash repurchases after specified events
  • Financing risk: insufficient operating cash flow could force asset sales, debt restructuring or highly dilutive financing
  • Litigation risk: potential XOMA Acquisition litigation disclosed, though not currently expected to be material

AI summary of the LGND 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Earnings release covers three and nine months ended September 30, 2026
  • Exhibit 99.1 contains Ligand’s financial results and provides the substantive investor detail

Item EX-99.1: Item EX-99.1

  • Q3 royalty revenue $70.3M, up 51% YoY, confirming XOMA assets and core products are accelerating recurring revenue
  • Total revenue $78.7M, down 32% YoY, distorted by $53.1M of prior-year Pelthos-related income
Filed Sep 24, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Ligand financing agreement with AvenCell Therapeutics, a clinical-stage developer of controllable allogeneic CAR-T therapies
  • Transaction provides AvenCell up to $47 million in financing
Filed Sep 22, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Ligand acquired royalty and milestone rights to Santen’s Ryjunea from Sydnexis
  • $23 million upfront payment creates near-term cash outflow for future contingent revenue

AI summaries of LGND 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LGND

Don't miss the next LGND filing

  • Alerts as it files. A push when LGND files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LGND, by share count.
  • Ask anything. An AI agent that reads every LGND filing and answers with sources.

LGND alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
KOZARICH JOHN WSellNov 12, 2026$325.00
Zimmermann MartineSellNov 12, 2026$318.17
Aryeh JasonSellNov 10, 2026$320.20
Aryeh JasonSellNov 10, 2026$320.02
Aryeh JasonSellNov 10, 2026$320.10
Aryeh JasonSellNov 10, 2026$320.00
Aryeh JasonSellNov 10, 2026$320.00
Aryeh JasonSellNov 10, 2026$319.99

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$167.1M$268.1M
Operating Income--$22.6M$41.0M
Net Income$52.2M-$4.0M$124.5M
Op. Margin--13.5%15.3%
Net Margin--2.4%46.4%
Balance Sheet
Total Assets$787.2M$941.8M$1.6B
Equity-$830.4M$1.0B
ROE--0.5%12.2%
Per Share
EPS$2.94$-0.22$6.13
Cash Flow
Operating CF-$97.0M$49.4M
CapEx$3.5M$1.8M$452K

Source: XBRL data in LIGAND PHARMACEUTICALS INC (LGND)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LGND share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LGND shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202632$3.37B
Q2 202632$3.42B
Q1 202631$1.95B
Q4 202528$1.70B
Q3 202529$1.58B
Q2 202528$922.6M
Q1 202527$543.6M
Q4 202422$507.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 229 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LGND filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 12, 2026--
4Nov 6, 2026--
4Nov 4, 2026--
4Nov 3, 2026--
10-QOct 30, 2026Analysis
8-KOct 29, 2026Analysis-
4Oct 6, 2026--
4Sep 24, 2026--
8-KSep 24, 2026Analysis-
8-KSep 22, 2026Analysis-
4Sep 14, 2026--
4Sep 8, 2026--
8-KSep 2, 2026Analysis-
4Aug 14, 2026--
4Aug 14, 2026--
SC 13GAug 13, 2026-
10-QAug 7, 2026Analysis
8-KAug 6, 2026Analysis-
4Aug 4, 2026--
8-KJul 14, 2026Analysis-
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--

Related Health Care companies

All Health Care →

LGND SEC filings: frequently asked questions

Are LGND insiders buying or selling?

In the last 90 days, LIGAND PHARMACEUTICALS INC (LGND) officers, directors and 10% owners reported no open-market purchases and 40 open-market sales worth $7.4 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold LGND stock?

As of September 30, 2026, the largest LIGAND PHARMACEUTICALS INC (LGND) holders among the 13F filers tracked by SignalX were BlackRock ($972.2 million), Invesco Ltd ($469.7 million), Vanguard Portfolio Management LLC ($347.4 million), Franklin Resources ($288.4 million), Vanguard Capital Management LLC ($271.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was LGND's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), LIGAND PHARMACEUTICALS INC (LGND) reported revenue of $268.1 million (up 60.4% from FY2024) and net income of $124.5 million. Diluted EPS was $6.13. The figures come from the XBRL data in the 10-K.

What are the main risks in LGND's latest 10-K?

In the 10-K filed February 27, 2026, LIGAND PHARMACEUTICALS INC (LGND) flagged: Regulatory risk: Section 162(m) limitation increased tax expense by $3.9 million (156%) in 2024 affecting effective tax rate. Macroeconomic threat: $460 million 2030 Notes issued in August 2025 increases interest expense by $1.7 million (55%) vs prior year. (AI summary of the Risk Factors section.)

What did LGND report in its latest 8-K?

LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Earnings release covers three and nine months ended September 30, 2026.

What are the latest LGND SEC filings?

LIGAND PHARMACEUTICALS INC (LGND) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 16, 2026.

What is LGND's SEC CIK number?

LIGAND PHARMACEUTICALS INC (LGND)'s SEC Central Index Key (CIK) is 886163. EDGAR lists every LGND filing under that number.

Ask anything about LGND

The research agent reads LGND's filings, financials, insider trades and 13F holders, then answers with sources.